---
title: "Palvella Therapeutics, Inc. (PVLA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/PVLA.US.md"
symbol: "PVLA.US"
name: "Palvella Therapeutics, Inc."
industry: "Biotechnology"
---

# Palvella Therapeutics, Inc. (PVLA.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [alvellatx.com](https://alvellatx.com) |

## Company Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial f...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -56.05 | 546/606 | - | - | - |
| PB | 46.90 | 433/606 | 27.67 | 13.13 | 4.67 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-24T05:00:00.000Z

Total Analysts: **15**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 15 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 132.07 |
| Highest Target | 267.00 |
| Lowest Target | 193.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/PVLA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/PVLA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/PVLA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.